

Interim 2020

- COVID-19 global pandemic has adversely affected the Group's results for the period
- All sites across the Group closed mid-March and started to re-open in June 2020
- >70% of our cinemas have reopened except for 200 theatres in the US (mostly CA and NY), 6 in the UK and 11 in Israel
- Implementation of CinemaSafe health and safety protocols to ensure the safety of customers and employees
- **X** Key liquidity actions taken including cost reduction to ensure cash preservation
- Secured \$361m additional liquidity during the period
- ★ June 2020 covenant waived
- ★ Termination of Cineplex transaction in June 2020
- We continue our efforts to mitigate the effect of the closures and preserve cash during re-opening



H1 FINANCIALS AT A GLANCE

Admissions

47.5m

(65.1%)

Revenue

\$712.4

(66.9%)

Adj. EBITDA IFRS 16

\$53.0m

(93.0%)

Adj. EBITDA Pre-IFRS 16

(\$237.0m)

Adj. PBT

(\$567.7m)

Free Cash Flow pre growth Capex

(\$170m)

Net Debt Pre-IFRS 16

\$4.0bn

Adj. EPS

(\$31.8c)

Key Liquidity Actions

Secured rent relief and deferral with most of our landlords

Discussed with all key suppliers to reduced costs and implement payment plans

Furloughed the majority of our part time, hourly cinema employees and head office employees

Partially deferred salaries for most of the HQ and full time employees and deferred full salaries of Group Executives and Directors

Accessed government support programs: US CARES Act, UK furlough scheme, Business rates relief

Secured \$361m additional liquidity

6

8

Suspended quarterly dividend payments

Suspended all unnecessary capital expenditure

Group Profit and Loss – IFRS 16

\$m	H1 2020	H1 2019
Revenue	712.4	2,151.2
Cost of sales	(624.9)	(1,356.6)
Gross profit	87.5	794.6
G&A	(52.0)	(60.7)
Cash generated from JV	17.5	24.7
Adjusted EBITDA	53.0	758.6
D&A ¹	(349.8)	(345.9)
Adj. Operating profit	(296.8)	412.7
Net finance costs ²	(270.9)	(256.6)
Adj. Profit before tax	(567.7)	156.1
Tax charge	131.7	(27.5)
Adj. Profit after tax	(436.0)	128.6
Adjusted diluted EPS (cents)	(31.8c)	9.4

COVID-19 materially impacted our half year results starting March

Incurred \$955m impairment charge resulting in Net statutory loss of (\$1,583m)

Includes: \$17.5m cash contribution from JVs

Excludes:

- Transaction and reorganisation costs \$25.4m
- COVID-19 related costs of \$12.5m
- Legal costs of \$9.2m
- Other costs of \$0.6m


Net finance costs are:

- interest expense on bank loans of \$72.9m
- Interest income of \$5.0m
- non-cash interest of \$203.0m

¹⁾ Excludes amortisation of intangibles created on acquisition of \$12.9m

Excludes Movement on financial derivatives, Unwind of net investment hedge and Foreign exchange translation gains and losses


H1 2020 Free Cash Flow



H1 2020 ADJ. Net Debt



4.0bn Net debt as of June 2020





- + \$110.8m incremental RCF facility (undrawn)
- + \$250m private loan

Covenant waiver for June 2020 testing

December 2020 testing reset to 9.0x

Commenced covenant waiver discussions

Note: Excludes lease liability

Outlook


- Commenced covenant waiver discussions with banking group for December 2020
- Continue to explore additional sources of liquidity
- Rent negotiations ongoing for further deferral and discount
- Continue cost control and monitoring following cinema re-opening
- **Continue cash preservation initiatives**
- Steady performance of re-opened sites in ROW territories and initial admission build-up in the UK and US driven by the release of "Tenet" and local movies
- Encouraged by the upcoming film release



Key Operating Highlights

- Managed operations during cinema shut downs with furlough of employees in 10 countries
- ☆ Continued communication with all employees through shutdown and introduction of hardship fund
- Negotiated agreements with most landlords for deferred payments/discounts
- Reached understandings with key suppliers to reduce operating costs and implement payment plans
- Achieved significant cost cutting measures post re-opening to improve future performance
- Maintained good relationship with studios partners
- Led local discussions with governments and industry associations in all markets
- Re-opened 9 out of 10 territories with Israel closed
- Steady performance of re-opened sites in ROW territories and initial admission build-up in the UK and US driven by the release of "Tenet" and local movies
- Re-activated Unlimited membership in the US, UK and Poland

Cinema Closures and Re-opening timetable



Safety measures implemented

OUR SAFETY MEASURES



Booking

Contactless Payment



and PPF



















Cleaning


- Daily health screenings for employees
- **Employees and guests required to wear masks**
- Increased fresh air intake
- Online/App purchase of concessions
- **Auditorium capacity reduced**
- Seat sanitizing between showings



Implementation of CinemaSafe health and safety protocols prepared and launched with NATO and supported and developed by leading epidemiologists


Case Study – China re-opening





Cineworld Case Study – Hungary





What's next post Re-opening


- Ensure employee and customer health & safety
- Continue close relationships with Hollywood studios and key industry players
- ★ Lobby government to reduce restrictions
- Continue roll-out of Unlimited across our territories
- Curtailing capex spend during recovery whilst keeping technological competitive edge
- Working with our real estate partners to improve current deals
- Re-evaluation and optimisation of workforce levels in all territories
- Ensure the continued financial health of Cineworld
- Assess and evaluate new partnership opportunities

US Refurbishments - Irvine, CA

BEFORE




AFTER



US Refurbishments - Irvine, CA

BEFORE



AFTER




US Refurbishments





US Refurbishments – Union Square, NY



2020 film slate



2021 film slate























































